NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $105.00 +5.73 (+5.77%) (As of 09/12/2024 ET) Add Compare Share Share Today's Range$95.48▼$105.0750-Day Range$78.36▼$105.0052-Week Range$76.53▼$117.98Volume1.84 million shsAverage Volume715,351 shsMarket Capitalization$24.96 billionP/E Ratio210.00Dividend YieldN/APrice Target$109.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3.9% Upside$109.09 Price TargetShort InterestHealthy1.09% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.66Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.80) to ($2.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector706th out of 936 stocksBiological Products, Except Diagnostic Industry125th out of 155 stocks 2.3 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.09% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 16.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BioNTech is 306.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BioNTech's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 2.6 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for BioNTech this week, compared to 9 articles on an average week.Search Interest33 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($2.80) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 210.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 131.23.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 210.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 136.24.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsBlacklisted by AI: Guilty Until Proven Innocent!AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.Watch this urgent video to find out how! About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesAugust 19, 2024 | marketbeat.comModerna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (BNTX)Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.August 12, 2024 | marketbeat.comNovavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (BNTX)Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.September 12, 2024 | Weiss Ratings (Ad)Blacklisted by AI: Guilty Until Proven Innocent!AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.September 12 at 7:13 AM | msn.comGSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTechSeptember 11 at 9:33 AM | markets.businessinsider.comPromising BNT327 Data Bolsters BioNTech’s Buy Rating, With a Target of $171September 11 at 9:33 AM | marketwatch.comBioNTech SE ADR rises Tuesday, still underperforms marketSeptember 11 at 9:33 AM | seekingalpha.comBioNTech's Low Valuation, Many Shots On Goal Make It A BuySeptember 11 at 1:51 AM | americanbankingnews.comBioNTech Sees Unusually Large Options Volume (NASDAQ:BNTX)September 12, 2024 | Weiss Ratings (Ad)Blacklisted by AI: Guilty Until Proven Innocent!AI has garnered a lot of attention post the launch of ChatGPT, and rightly so. But here's a chilling fact a lot of people don't know: For decades, agencies like the NSA have been using AI to illegally snoop into the private lives of millions of Americans.September 9 at 11:55 PM | markets.businessinsider.comJ.P. Morgan Sticks to Its Sell Rating for BioNTech SE (BNTX)September 6, 2024 | benzinga.comModerna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study ShowsSeptember 5, 2024 | globenewswire.comBioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024September 4, 2024 | finance.yahoo.comTempus Announces Real World Data Collaboration with BioNTechSeptember 4, 2024 | markets.businessinsider.comTempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology PipelineSeptember 3, 2024 | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)September 3, 2024 | msn.comUK, Taiwan Approve Moderna's Updated COVID-19 ShotSeptember 3, 2024 | marketwatch.comBioNTech SE ADR outperforms market despite losses on the daySeptember 3, 2024 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) versus BioNTech (NASDAQ:BNTX) Head to Head ComparisonSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/12/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$109.09 High Stock Price Target$171.00 Low Stock Price Target$85.00 Potential Upside/Downside+13.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio192.46 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins-18.69% Pretax Margin-8.75% Return on Equity-2.54% Return on Assets-2.24% Debt Debt-to-Equity Ratio0.01 Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$2.69 billion Price / Sales8.50 Cash Flow$5.42 per share Price / Cash Flow17.74 Book Value$92.17 per share Price / Book1.04Miscellaneous Outstanding Shares237,726,000Free Float192,083,000Market Cap$22.88 billion OptionableOptionable Beta0.23 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $823.67kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $846.46kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $817.16kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $612.05kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInstitutional OwnershipSanctuary Advisors LLCBought 2,558 shares on 9/5/2024Ownership: 0.001%Granite Bay Wealth Management LLCBought 18,459 shares on 8/21/2024Ownership: 0.008%Truist Financial CorpSold 678 shares on 8/21/2024Ownership: 0.007%Employees Retirement System of TexasBought 4,115 shares on 8/15/2024Ownership: 0.013%Millennium Management LLCSold 2,800 shares on 8/15/2024Ownership: 0.000%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE has shown resilience in the market despite recent challenges, indicating strong potential for growth. The company's innovative approach to developing immunotherapies for cancer and infectious diseases positions it well in the biotechnology sector. Recent institutional investments in BioNTech SE, such as Primecap Management Co. CA boosting its stake, reflect confidence from major players in the market. With a market capitalization of $20.25 billion, BioNTech SE is a significant player in the industry, offering stability and growth opportunities. The company's focus on cutting-edge research and development could lead to breakthrough treatments, driving stock price appreciation. Cons Investors should be bearish about investing in BioNTech SE for these reasons: The company's recent earnings report showed a significant miss on EPS, which may raise concerns about its financial performance. BioNTech SE's revenue decline of 23.3% compared to the previous year indicates potential challenges in maintaining growth. Despite institutional investments, the stock's price-to-earnings ratio of 170.38 may be considered high, posing a risk for investors. The company's net margin of 4.01% suggests relatively low profitability compared to industry peers, impacting potential returns for investors. Analysts forecasting negative EPS for the current fiscal year could lead to short-term volatility in the stock price, affecting investor confidence. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX stock has decreased by 0.5% and is now trading at $105.00. View the best growth stocks for 2024 here. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings data on Monday, August, 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by $1.34. BioNTech's quarterly revenue was down 23.3% on a year-over-year basis. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. Does BioNTech have any subsidiaries? BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more. When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's top institutional shareholders include Baillie Gifford & Co. (3.48%), Primecap Management Co. CA (2.01%), Deerfield Management Company L.P. Series C (0.25%) and Candriam S.C.A. (0.24%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX) and Gilead Sciences (GILD). This page (NASDAQ:BNTX) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersWhat Kamala WON’T Do if she wins the electionA lot of folks have their fingers crossed about Kamala Harris winning the election… After all, she’s promis...Banyan Hill Publishing | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
